<DOC>
	<DOCNO>NCT01626677</DOCNO>
	<brief_summary>This long term follow-up study investigate safety efficacy CARTISTEM® , human umbilical cord blood-derived mesenchymal stem cell , repair cartilage injury defect , compare microfracture . Subjects participate complete Phase III trial ( NCT01041001 ) track 60 month post-treatment timepoint .</brief_summary>
	<brief_title>Follow-Up Study CARTISTEM® Versus Microfracture Treatment Knee Articular Cartilage Injury Defect</brief_title>
	<detailed_description>This long term follow-up study perform assess long-term safety efficacy CARTISTEM® , human umbilical cord blood-derived mesenchymal stem cell , repair cartilage injury defect , compare microfracture . Subjects , either administer CARTISTEM treat conventional microfracture primary phase III study ( NCT01041001 ) , observe use various subjective knee assessment MRI T2 map 60 month post-treatment timepoint .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>Patients knee joint cartilage defect injury ICRS ( International Cartilage Repair Society ) Grade 4 confirm arthroscopy ( At screening , patient diagnose MRI may include ) Male female patient least 18 year age Patients whose lesion ( unilateral joint ) 2 ㎠ ~ 9㎠ size Patients articular swell , tenderness active range motion Grade 2 Patients pain affect joint 60mm 100mm VAS ( visual analogue scale ) Patients adequate blood coagulation activity : PT ( INR ) &lt; 1.5 , APTT &lt; 1.5×control Patients adequate renal function : Creatinine ≤ 2.0 ㎎/㎗ , level proteinuria measure Dipstick : trace less Patients adequate hepatic function : Bilirubin ≤ 2.0 ㎎/㎗ , AST/ALT ≤ 100 IU/L Patients receive surgery radiation therapy affect joint within past 6 six week , recover side effect past treatment Female patient childbearing potential must agree practice adequate method birth control prevent pregnancy study Patients whose physical examination result show ligament instability Grade II ( Grade 0 : none , Grade I : 05 mm , Grade II : 510 mm , Grade III : &gt; 10 mm ) Patients voluntarily agree enroll study sign informed consent form Patients autoimmune disease medical history Patients infection require parenteral administration antibiotic Patients myocardial infarction , ischemic heart failure , serious heart condition uncontrolled hypertension , medical history disease Patients serious internal disease Patients currently pregnant nursing Patients psychotic disease , epilepsy , history disease Patients alcohol abuse Patients smoke excessively Patients chronic inflammatory articular disease rheumatoid arthritis Patients enrol clinical trial within past four week Patients administer immunosuppressant Cyclosporin A azathioprine within past six week Patients whose physical examination result show ligament instability Grade II ( Grade 0 : none , Grade I : 05 mm , Grade II : 510 mm , Grade III : &gt; 10 mm ) Patients known history hypersensitivity/allergy gentamicin Patients principal investigator considers inappropriate clinical trial due reason list</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Umbilical Cord Blood</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Cartilage injury</keyword>
	<keyword>Osteoarthritis</keyword>
</DOC>